All In Biotech

Drug Trial Radar · NCT00531947

Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression

A Phase IV, Double-Blind, Placebo-Controlled, Randomized, Flexible Dose Study of the Safety and Efficacy of EMSAM in Adolescents With Major Depression

Last checked: Nov 20, 2026Latest source record: Jan 15, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 308 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

308

Actual

Start

Jul 2007

Primary completion

Oct 2010

Study completion Oct 2010

Sponsor

Lead sponsor
Somerset PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Sep 19, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of your participation in this study is to help answer the following research question: Whether 12-week administration of EMSAM (selegiline transdermal system) is safe and effective for the treatment of adolescents (aged 12 through 17 years) with Major Depressive Disorder (MDD).

Conditions

  • Major Depressive Disorder

Interventions

  • Selegiline Transdermal SystemDrug

    EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study

  • PlaceboDrug

    Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CDRS-R Total Score (Child) (mITT w/LOCF Population) Week 12Time frame: baseline and 12 Weeks

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Dr. Nelson Handal

    Dothan, Alabama

  • Dr. Mohammed Bari

    National City, California

  • Dr. Michael McManus

    San Diego, California

  • Dr. Elias Sarkis

    Gainesville, Florida

  • Dr. Scott Segal

    North Miami, Florida

  • Dr. Mary Stedman

    Tampa, Florida

  • Dr. Irving Kolin

    Winter Park, Florida

  • Dr. Rory Murphy

    Overland Park, Kansas

  • Dr. Andrew Sediloo

    Owensboro, Kentucky

  • Dr. Bruce Waslick

    Springfield, Massachusetts

  • Dr. Christopher Kratochvil

    Omaha, Nebraska

  • Dr. Ann Childress

    Las Vegas, Nevada

  • Dr. Melissa DelBello

    Cincinnati, Ohio

  • Dr. Leland Dennis

    Oklahoma City, Oklahoma

  • Dr. David Brown

    Austin, Texas

  • Dr. Alain Katic

    Bellaire, Texas

  • Dr. Graham Emslie

    Dallas, Texas

  • Dr. Mary Shemo

    Charlottesville, Virginia

  • Dr. John Gilliam

    Richmond, Virginia

  • Dr. Arifulla Khan

    Bellevue, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.